Cytokines (IL1β,IL6,TNFα) and serum cortisol levels may not constitute reliable biomarkers to identify individuals with post-acute sequelae of COVID-19

Abstract

Background:

Post-acute sequelae of COVID-19 (PASC) comprise a broad spectrum of symptoms such as fatigue, general weakness, compromised attention and sleep or anxiety disorders. PASC represents a medical and socio-economic challenge.

Objectives:

Our study evaluated cytokines (IL-1β, IL-6 and TNFα) and cortisol levels in a cohort of typical patients with PASC, suffering concentration problems, fatigue and difficulties finding words.

Design:

This was a prospective cohort study. Four groups were analysed and compared: those who had never contracted SARS-CoV-2 (n = 13), infected but had no PASC (n = 34), infected with former PASC that resolved (n = 40) and patients with ongoing PASC after infection (n = 91).

Methods:

Cytokine and cortisol serum levels were determined in patients’ blood samples.

Results:

Cytokine levels of IL-1β, IL-6, TNFα and cortisol levels did not differ between groups analysed.

Conclusion:

This may indicate a non-organic/psychosomatic genesis of PASC; further studies are needed to elucidate the underlying causes of PACS, and non-organic causes should not be overlooked.

Plain language summary

Without clear biological markers for people who will continue to present with post-acute sequelae of COVID-19 (PASC) should we now focus on psychological factors?

Many people across the globe are still suffering from post-acute sequelae of COVID-19 (PASC), commonly called post-COVID. Typical symptoms of PASC include severe tiredness (fatigue), concentration deficits (brain fog) or difficulty finding words. We need a better understanding of how these symptoms arise to find ways to help patients. Our team of researchers set out to explore this. We posed the question: could measurements of immune system activity provide an identifier for people who are susceptible to post-COVID?

The participants in our study were divided into four groups: 1. A group of 13 people who had never contracted SARS-CoV-2. 2. A group of 34 people who had been infected with SARS-CoV-2 but had no PASC. 3. A group of 40 people who had been infected with SARS-CoV-2 and had already suffered from PASC that had now resolved. 4. A group of 91 people who were no longer sick with COVID-19 but were still suffering from PASC.

Serum samples from all participants were taken to measure cytokine and cortisol levels. People with PASC could not be identified by testing their blood samples for cytokines (IL-1β, IL-6, TNFα) or cortisol. No difference between the four groups was found on any marker. Measuring these cytokines or cortisol is, therefore, unlikely to be useful in predicting which patients will suffer from PASC. Continuation of symptoms long after COVID-19 has passed is distressing for many people worldwide. Psychological factors may play a role and need to be studied further in order to help this patient population.

Keywords

biomarker immuno-profile post-acute sequela of COVID-19 SARS-CoV-2

Introduction

Post-acute sequelae of COVID-19 (PASC) – for example, fatigue, palpitations, attention, sleep and anxiety disorders^1–3 – are thought to affect up to 10% of hospitalized patients, albeit recent studies pointing towards significantly lower incidences, in particular since the emergence of the omicron virus variant.⁴ Despite the acceptance that PASC has precipitated significant medical and socio-economic problems, the underlying causes of PASC are yet unclear. Multifactorial origins for these symptoms are being explored, and psychosomatic factors, viral persistence, autoimmunity and a persistent inflammatory response have all been suggested as potential mechanisms.⁵ Understanding PASC pathophysiology, and the identification of biomarkers could be clinically valuable – particularly in predicting the risk of progressing to PASC.⁶

A broad variety of potential aetiologies and biomarkers have already been proposed in PASC.^7,8 For example, it has been suggested that an increase in α2-antiplasmin may lead to microclots and impaired fibrinolysis in individuals with PASC.⁹ Moreover, increased platelet activation and vascular endothelial dysfunction may be involved in the condition.⁵ Finally, the persistence of SARS-CoV-2 could induce microbiota dysbiosis, autoimmunity and immune priming.⁵ Hence, the spectrum of suggested mechanisms is broad,¹⁰ as well as suggested surrogate markers of PASC, such as antibodies.¹¹ Interesting biomarkers that offer a convenient measurement technique and are potentially compatible with suggested PASC pathophysiology have recently been described, namely the cytokine panel IL-1β (Interleukin-1β), IL-6 (Interleukin-6) and TNFα (tumour necrosis factor alpha),^12,13 decreased cortisol levels and immune profiling.^14,15 If the pathophysiology of PASC is based on an excessive immune reaction or aberrant hormone release, then determining these parameters could provide a viable biomarker.

As we previously have not yet been able to find any laboratory abnormalities, obvious immunological changes, increased inflammation or clinical cues of a cortisol deficiency in our PASC patients,¹⁶ we have strived to reproduce cytokine signatures and altered cortisol levels in a cohort of PASC patients.

Methods

Study design and cohort

This study was conducted following the ethical principles of the Declaration of Helsinki. Informed written consent was obtained from all participants.

In total, n = 178 participants were analysed in this study, 130 participants fulfilled the WHO Delphi consensus criteria for PASC¹⁷ and were included. A previous positive PCR (polymerase chain reaction) test had confirmed SARS-CoV-2 infection in all participants. All individuals were recruited from the post-COVID-19 outpatient centre at the Department of Neurology, University Medicine Essen, Germany, between January 2021 and March 2023. In addition, n = 13 participants without previous SARS-CoV-2 infection were recruited. To ensure that the group of patients who had never contracted SARS-CoV-2 had no previous exposure to the SARS-CoV2-free status of the control group, antibody testing was performed in five cases, while we relied on assessing past medical history in eight cases.

Participants were stratified into four groups: those who had never contracted SARS-CoV-2 (n = 13); those who had been infected with SARS-CoV-2 but did not experience PASC (n = 34); those who had been infected with SARS-CoV-2 and experienced PASC that resolved over time (n = 40) and those with ongoing PASC post-COVID-19 (n = 91).

Cortisol levels and cytokine concentration in serum

All serum samples were collected between 8.00 and 11.00 a.m. between January 2021 and March 2023. Serum cortisol levels were determined with the Siemens Atellica^® IM Analyzer (Siemens Healthineers, Erlangen, Germany). The Atellica^® IM Cortisol assay is a competitive chemiluminescence immunoassay with a detection limit of 13.80–2069.25 nmol/l, an intra-assay variation of 7.7% and an inter-assay variation of 2.7%. The instrument controls were performed according to the product inserts (manufacturer’s quality control). Serum cortisol is accredited according to DIN EN ISO 15189:2014. LEGENDplex Human B Cell Panel (13-plex, BioLegend) was used to determine serum IL-1β, IL-6 and TNFα cytokine levels.

Statistics

Differences for multiple groups were analysed using non-parametric Kruskal-Wallis-ANOVA with Dunnett’s multiple comparison tests after testing parametric distribution with the Shapiro-Wilk test. Pearson’s correlation was used to analyse cytokine and cortisol levels. All statistical analyses were done by SPSS (IBM Corp. Released 2020, IBM SPSS Statistics for macOS, Version 27.0; IBM Corp., Armonk, NY, USA). Graphs were drawn using GraphPad Prism (version 9.5.1 for macOS; GraphPad Software, San Diego, CA, USA). The level of significance was determined by p < 0.05.

Results

Demographics

Demographics between the four groups (those who had never contracted SARS-CoV-2, those who had been infected with SARS-CoV-2 but did not experience PASC, those who experienced PASC that resolved and those with ongoing PASC) were comparable, although patients in the group ‘no prior COVID-19’ were significantly younger, compared to the average age (p = 0.02).

Patients with preceding COVID-19, in most cases, experienced a mild to moderate course of infection (mild: 54.8%, moderate: 43.4%, severe: 1.8%) according to the severity scale implemented by Buonsenso et al.¹⁷ Of those participants who reported PASC (n = 131), the mean severity was 3.4 ± 2.5, according to the severity score established by Bahmer et al.¹⁸ in the COVIDOM study. PASC patients presented with a median duration of the symptoms 7 ± 7.4 months after the acute infection (Table 1). The most common symptoms reported were deficits in concentration (67.8%), fatigue (39.2%) and difficulties finding words (14.7%). There was no difference in comorbidities across the groups (data not shown). One patient was infected with SARS-CoV-2 despite preceding vaccination.

Table 1.

Demographic characteristics of studied chohorts and disease-related parameters for SARS-CoV2 infection.

Parameters	Total	No prior COVID-19	Never PASC	Resolved PASC	Ongoing PASC
Number	178	13	34	40	91
Age
Mean ± SD (years)	44.5 ± 13.9	33.4 ± 11.8	38.7 ± 16.3	46.6 ± 12.9	47.3 ± 12.6
Sex
Female (%)	66	63	65	61	66
Severity of COVID-19
Mild (%)	54.8		73.5	42.5	51.2
Medium (%)	43.4		26.5	55.0	46.6
Severe (%)	1.8			2.5	2.2
Hospitalization for acute infection (days)	3 (1.6%)	n.a.	0 (0%)	2 (5.0%)	1 (1.0%)
Time infection to study inclusion (months)	7 ± 7.4	n.a.	n.a.	5.5 ± 4.9	7.0 ± 8.1
Severity of PASC (severity score, Bahmer et al.)	3.4 ± 2.5	n.a.	n.a.	2.2 ± 1.2	3.8 ± 2.6

PASC, post-acute sequelae of COVID-19.

Serum cytokines

No differences between the stratified groups could be found for the cytokine levels of IL-1β, IL-6 and TNFα (Table 2; Figure 1). The three cytokines positively correlate within individuals. The strongest correlation was detected between IL-6 and TNFα (r = 0.89), followed by IL-1β/IL-6 (r = 0.64) and IL-1β/TNFα (r = 0.45, data not shown).

Table 2.

Levels of cytokines IL-1β, IL-6 and TNFα and levels of cortisol levels according to COVID-19/PASC status.

Parameters	Total	No prior COVID-19	Never PASC	Resolved PASC	Ongoing PASC
Number	165	12	29	39	85
Cytokine (pg/ml)
IL-1β (mean ± SD)	10.4 ± 18.4	14.9 ± 36.5	9.6 ± 13.6	9.7 ± 19.8	10.3 ± 15.5
IL-6 (mean ± SD)	4.7 ± 10.8	8.9 ± 25.9	4.8 ± 8.1	4.7 ± 10.4	4.1 ± 8.0
TNFα (mean ± SD)	5.6 ± 14.4	13.7 ± 37.7	6.0 ± 12.7	4.5 ± 8.7	4.8 ± 10.4
Number	142	12	24	34	72
Cortisol (mmol/l)
Mean ± SD	339.7 ± 141.3	298.4 ± 76.1	298.7 ± 97.7	331.8 ± 105.2	340.5 ± 112.6

PASC, post-acute sequelae of COVID-19.

Figure 1.

(a) Serum levels of IL-1β, IL-6 and TNFα (mean ± SD). (b) Serum levels of cortisol (mean ± SD) with upper limit (UL, 620 nmol/l) and lower limit (LL, 145 nmol/l) of normal.

Serum cortisol

No difference in serum cortisol levels between the groups was detected and serum cortisol levels were within the normal range in all groups (Table 2; Figure 1). No correlation was identified between individual participants’ serum cortisol levels and cytokine concentration (data not shown).

Discussion

In this study, cytokine levels of IL-1β, IL-6 and TNFα or cortisol levels did not show suitability as biomarkers to identify or objectify PASC. A prior study by Schulteiß et al. showed that after 8 months post-acute infection, patients with ongoing PASC show cytokine dysregulation. In particular, the triad of IL-1β, IL-6 and TNFα was identified to correlate with the presence of symptoms.¹³ Another study found reduced cortisol levels associated with PASC versus non-PASC.¹⁴ Surprisingly, however, cytokine and cortisol levels did not differ between the groups in our study. This is despite similar study populations concerning the distribution of demographic characteristics, the compatible spectrum of PASC and the use of the same methods and testing kits. However, the relatively small sample size and the unequal sample distribution of the four analysed groups must be regarded as limitations of our study.

Several reasons could account for the discrepancy in findings; for example, concomitant diseases in the participants could partially explain formerly reported higher cytokine levels. Bronchial asthma is associated with heightened cytokine levels¹⁹; analogously, these patients had higher cytokine levels in our study. Therefore, these conditions must be considered when interpreting cytokine levels in general. However, in the study by Schultheiß, a detailed characterization of the participant’s comorbidities is not provided.¹³ Cortisol levels had no diagnostic value in identifying PASC and showed a broad inter-patient variability. Different pretest conditions might affect the variability of cortisol levels, such as the time of the blood draw and concomitant diseases.

Previous studies have suggested various biomarkers in PASC,^8,15,20 but small sample sizes and lack of cohort stratification may limit some of these studies. Therefore, caution is advised concerning drawing a broad conclusion from studies with moderate sample sizes, unadjusted risk factors or unmeasured characteristics.²¹

In summary, the above-mentioned cytokines and cortisol are not appropriate biomarkers. The results of this study are consistent with our previous findings and those of others who did not find any laboratory changes and have suggested a non-organic/psychosomatic genesis of PASC.^16,21,22 Further studies are necessary to elucidate the pathophysiology of PASC¹⁰ but non-organic causes should not be overlooked.

Footnotes

Acknowledgements

None.

Declarations

ORCID iDs

Michael Fleischer

Livia Asan

Mark Stettner

References

Huang

Pinto

Borelli

, et al. COVID symptoms, symptom clusters, and predictors for becoming a long-hauler: looking for clarity in the haze of the pandemic. medRxiv. http://medrxiv.org/lookup/doi/10.1101/2021.03.03.21252086 (2021, accessed 7 July 2023).

Premraj

Kannapadi

Briggs

, et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: a meta-analysis. J Neurol Sci 2022; 434: 120162.

Schou

Joca

Wegener

, et al. Psychiatric and neuropsychiatric sequelae of COVID-19: a systematic review. Brain Behav Immun 2021; 97: 328–348.

Hernández-Aceituno

García-Hernández

Larumbe-Zabala

COVID-19 long-term sequelae: omicron versus alpha and delta variants. Infect Dis Now 2023; 53: 104688.

Davis

McCorkell

Vogel

, et al. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 2023; 21: 133–146.

Kings College. COVID symptom study. How long does COVID-19 last? https://covid19.joinzoe.com/post/covid-long-term?fbclid=IwAR1RxIcmmdL-EFjh_aI-. (2020, accessed 12 March 2023).

Sudre

Murray

Varsavsky

, et al. Attributes and predictors of long COVID. Nat Med 2021; 27: 626–631.

Yuan

Chen

, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 2022; 185: 881–895.e20.

Pretorius

Vlok

Venter

, et al. Persistent clotting protein pathology in long COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol 2021; 20: 172.

10.

Stefanou

M-I

Palaiodimou

Bakola

, et al. Neurological manifestations of long-COVID syndrome: a narrative review. Ther Adv Chronic Dis 2022; 13: 20406223221076890.

11.

Iwasaki

Putrino

Why we need a deeper understanding of the pathophysiology of long COVID. Lancet Infect Dis 2023; 23: 393–395.

12.

Kappelmann

Dantzer

Khandaker

Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19. Psychoneuroendocrinology 2021; 131: 105295–105295.

13.

Schultheiß

Willscher

Paschold

, et al. The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep Med 2022; 3: 100663.

14.

Kanczkowski

Beuschlein

Bornstein

SR.

Is there a role for the adrenal glands in long COVID?

Nat Rev Endocrinol 2022; 18: 451–452.

15.

Klein

Wood

Jaycox

, et al. Distinguishing features of Long COVID identified through immune profiling. medRxiv. http://medrxiv.org/lookup/doi/10.1101/2022.08.09.22278592 (2022, accessed 1 February 2024).

16.

Fleischer

Szepanowski

Tovar

, et al. Post-COVID-19 syndrome is rarely associated with damage of the nervous system: findings from a prospective observational cohort study in 171 patients. Neurol Ther 2022; 11: 1637–1657.

17.

Buonsenso

Parri

De Rose

, et al. Toward a clinically based classification of disease severity for paediatric COVID-19. Lancet Infect Dis 2021; 21: 22.

18.

Bahmer

Borzikowsky

Lieb

, et al. Severity, predictors and clinical correlates of post-COVID syndrome (PCS) in Germany: a prospective, multi-centre, population-based cohort study. eClinicalMedicine 2022; 51: 101549.

19.

Weckmann

Thiele

Liboschik

, et al. Cytokine levels in children and adults with wheezing and asthma show specific patterns of variability over time. Clin Exp Immunol 2021; 204: 152–164.

20.

Proal

VanElzakker

MB.

Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol 2021; 12: 698169.

21.

Sneller

Jason Liang

Marques

, et al. A longitudinal study of COVID-19 sequelae and immunity: baseline findings. Ann Intern Med 2022; 175: 969–979.

22.

Matta

Wiernik

Robineau

, et al. Association of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms among french adults during the COVID-19 pandemic. JAMA Intern Med 2022; 182: 19.